366 related articles for article (PubMed ID: 18318465)
1. Benzyl ether-linked glucuronide derivative of 10-hydroxycamptothecin designed for selective camptothecin-based anticancer therapy.
Leu YL; Chen CS; Wu YJ; Chern JW
J Med Chem; 2008 Mar; 51(6):1740-6. PubMed ID: 18318465
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and Antitumor Properties of BQC-Glucuronide, a Camptothecin Prodrug for Selective Tumor Activation.
Prijovich ZM; Burnouf PA; Chou HC; Huang PT; Chen KC; Cheng TL; Leu YL; Roffler SR
Mol Pharm; 2016 Apr; 13(4):1242-50. PubMed ID: 26824303
[TBL] [Abstract][Full Text] [Related]
3. Design and synthesis of water-soluble glucuronide derivatives of camptothecin for cancer prodrug monotherapy and antibody-directed enzyme prodrug therapy (ADEPT).
Leu YL; Roffler SR; Chern JW
J Med Chem; 1999 Sep; 42(18):3623-8. PubMed ID: 10479293
[TBL] [Abstract][Full Text] [Related]
4. Cancer chemotherapy: a SN-38 (7-ethyl-10-hydroxycamptothecin) glucuronide prodrug for treatment by a PMT (Prodrug MonoTherapy) strategy.
Angenault S; Thirot S; Schmidt F; Monneret C; Pfeiffer B; Renard P
Bioorg Med Chem Lett; 2003 Mar; 13(5):947-50. PubMed ID: 12617927
[TBL] [Abstract][Full Text] [Related]
5. Selective cancer therapy by extracellular activation of a highly potent glycosidic duocarmycin analogue.
Chen KC; Schmuck K; Tietze LF; Roffler SR
Mol Pharm; 2013 May; 10(5):1773-82. PubMed ID: 23448264
[TBL] [Abstract][Full Text] [Related]
6. A humanized immunoenzyme with enhanced activity for glucuronide prodrug activation in the tumor microenvironment.
Chen KC; Wu SY; Leu YL; Prijovich ZM; Chen BM; Wang HE; Cheng TL; Roffler SR
Bioconjug Chem; 2011 May; 22(5):938-48. PubMed ID: 21443266
[TBL] [Abstract][Full Text] [Related]
7. New Taxol (paclitaxel) prodrugs designed for ADEPT and PMT strategies in cancer chemotherapy.
Alaoui AE; Saha N; Schmidt F; Monneret C; Florent JC
Bioorg Med Chem; 2006 Jul; 14(14):5012-9. PubMed ID: 16554162
[TBL] [Abstract][Full Text] [Related]
8. A new cyclopamine glucuronide prodrug with improved kinetics of drug release.
Renoux B; Legigan T; Bensalma S; Chadéneau C; Muller JM; Papot S
Org Biomol Chem; 2011 Dec; 9(24):8459-64. PubMed ID: 22042246
[TBL] [Abstract][Full Text] [Related]
9. Anti-tumour activity and toxicity of the new prodrug 9-aminocamptothecin glucuronide (9ACG) in mice.
Prijovich ZM; Chen BM; Leu YL; Chern JW; Roffler SR
Br J Cancer; 2002 May; 86(10):1634-8. PubMed ID: 12085215
[TBL] [Abstract][Full Text] [Related]
10. Beta-glucuronidase-mediated drug release.
de Graaf M; Boven E; Scheeren HW; Haisma HJ; Pinedo HM
Curr Pharm Des; 2002; 8(15):1391-403. PubMed ID: 12052215
[TBL] [Abstract][Full Text] [Related]
11. Effect of pH and human serum albumin on the cytotoxicity of a glucuronide prodrug of 9-aminocamptothecin.
Prijovich ZM; Leu YL; Roffler SR
Cancer Chemother Pharmacol; 2007 Jun; 60(1):7-17. PubMed ID: 16983566
[TBL] [Abstract][Full Text] [Related]
12. Glucuronides in anti-cancer therapy.
Chen X; Wu B; Wang PG
Curr Med Chem Anticancer Agents; 2003 Mar; 3(2):139-50. PubMed ID: 12678908
[TBL] [Abstract][Full Text] [Related]
13. Duocarmycin-based prodrugs for cancer prodrug monotherapy.
Tietze LF; Schuster HJ; Schmuck K; Schuberth I; Alves F
Bioorg Med Chem; 2008 Jun; 16(12):6312-8. PubMed ID: 18524605
[TBL] [Abstract][Full Text] [Related]
14. Self-assembling nanowires of an amphiphilic camptothecin prodrug derived from homologous derivative conjugation.
He D; Zhang W; Deng H; Huo S; Wang YF; Gong N; Deng L; Liang XJ; Dong A
Chem Commun (Camb); 2016 Dec; 52(98):14145-14148. PubMed ID: 27869268
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and biological evaluations of a monomethylauristatin E glucuronide prodrug for selective cancer chemotherapy.
Legigan T; Clarhaut J; Renoux B; Tranoy-Opalinski I; Monvoisin A; Jayle C; Alsarraf J; Thomas M; Papot S
Eur J Med Chem; 2013 Sep; 67():75-80. PubMed ID: 23845743
[TBL] [Abstract][Full Text] [Related]
16. Preparation of a camptothecin prodrug with glutathione-responsive disulfide linker for anticancer drug delivery.
Xu Z; Wang D; Xu S; Liu X; Zhang X; Zhang H
Chem Asian J; 2014 Jan; 9(1):199-205. PubMed ID: 24136878
[TBL] [Abstract][Full Text] [Related]
17. A camptothecin-based, albumin-binding prodrug enhances efficacy and safety in vivo.
Cheng Z; Huang Y; Shen Q; Zhao Y; Wang L; Yu J; Lu W
Eur J Med Chem; 2021 Dec; 226():113851. PubMed ID: 34547508
[TBL] [Abstract][Full Text] [Related]
18. β-Glucuronidase-responsive prodrugs for selective cancer chemotherapy: an update.
Tranoy-Opalinski I; Legigan T; Barat R; Clarhaut J; Thomas M; Renoux B; Papot S
Eur J Med Chem; 2014 Mar; 74():302-13. PubMed ID: 24480360
[TBL] [Abstract][Full Text] [Related]
19. Activation of a camptothecin prodrug by specific carboxylesterases as predicted by quantitative structure-activity relationship and molecular docking studies.
Yoon KJ; Krull EJ; Morton CL; Bornmann WG; Lee RE; Potter PM; Danks MK
Mol Cancer Ther; 2003 Nov; 2(11):1171-81. PubMed ID: 14617791
[TBL] [Abstract][Full Text] [Related]
20. Pyrrolo[2,1-c][1,4]benzodiazepine-beta-glucuronide prodrugs with a potential for selective therapy of solid tumors by PMT and ADEPT strategies.
Kamal A; Tekumalla V; Raju P; Naidu VG; Diwan PV; Sistla R
Bioorg Med Chem Lett; 2008 Jul; 18(13):3769-73. PubMed ID: 18538566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]